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Abstract 
Objective
To assess the costs, effects, and cost-utility of an accelerated-physiotherapy 
programme versus a standard-physiotherapy programme following resurfacing hip 
arthroplasty. 
Design
A cost-utility analysis alongside a randomised controlled trial.
Setting
A United Kingdom National Health Service hospital and patients’ homes.
Subjects
Eighty male resurfacing hip arthroplasty patients randomised post-procedure to one 
of the two programmes.
Interventions
The accelerated-physiotherapy programme commenced in hospital with patients 
being fully weight-bearing, without hip precautions, and following a range of exercises 
facilitating gait re-education, balance and lower-limb strength. Standard-
physiotherapy commenced in hospital but hip precautions were used and exercises 
were only partially weight-bearing.  In both groups, patients continued with their 
exercises at home for an eight-week period.
Main Measures
Data on healthcare contacts were collected from patients out to 12 months and costed 
using unit costs from national sources. Information was also collected on patients’ 
costs. Health-related quality of life was measured using the EuroQol EQ-5D 
questionnaire and used to estimate quality adjusted life years to 12 months.  Mean 
costs and quality adjusted life years for each trial arm were compared.
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Results
On average, the accelerated-physiotherapy programme was less expensive (mean 
cost difference -£200; 95% confidence interval: -£656 to £255) and more effective 
(mean quality adjusted life years difference 0.13; 95% confidence interval: 0.05 to 
0.21) than standard-physiotherapy and had a high probability of being cost-effective. 
Conclusions
From the National Health Service perspective, an accelerated-physiotherapy 
programme for male patients undergoing RHA is very likely to be cost-effective when 
compared to a standard-physiotherapy programme.
ISRCTN: ISRCTN83876843[https://doi.org/10.1186/ISRCTN83876843]
Keywords
Cost-utility, randomised controlled trial, physiotherapy, rehabilitation, hip arthroplasty.
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1 Introduction
2 We previously demonstrated in a randomised controlled trial of young male 
3 patients who have undergone hip resurfacing arthroplasty, that an accelerated 
4 physiotherapy programme led to a measurable benefit in clinical outcomes (range 
5 of motion, hip flexion and hip extension) and quality-of-life at 12 months when 
6 compared with standard physiotherapy.1 The study showed patients were able to 
7 tolerate and receive greater benefit from a less precautionary and more intensive 
8 approach to rehabilitation.
9 However, it remains uncertain whether such benefits are realised at an increased 
10 cost. Given the scarcity of health care resources, this requires further 
11 investigation before decisions can be made about providing such a service as 
12 part of the National Health Service in England and Wales.
13 To the best of our knowledge, no other studies assessing the cost-effectiveness 
14 of accelerated or intensive physiotherapy programmes following resurfacing hip 
15 arthroplasty have been published. In this paper we report the findings from a cost-
16 utility analysis conducted alongside our aforementioned randomised controlled 
17 trial with a view to drawing conclusions about the likely cost-effectiveness of an 
18 accelerates physiotherapy programme following resurfacing hip arthroplasty. 
19
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1 Methods
2 Patients referred to the National Health Service Nuffield Orthopaedic Centre in 
3 Oxford in the United Kingdom for primary resurfacing hip arthroplasty from 2009 
4 to 2010 were assessed for inclusion into the study. Patients were excluded if they 
5 were listed for bilateral arthroplasty, minimally invasive surgery, or further lower 
6 limb joint surgery in the following 12 months, or were unable to provide informed 
7 consent. 
8
9 A computer generated the randomisation sequence, using blocks of 20. 
10 Treatment allocation was concealed from two research physiotherapists, who 
11 were blinded to treatment allocation. The sequence was concealed in numbered 
12 envelopes and opened sequentially by an administrator, who informed the clinical 
13 physiotherapist of group allocation. The clinical physiotherapists – who worked 
14 independently to the research team, were trained to avoid the failure of blinding 
15 and concealment. Further details of the trial have been published elsewhere.1
16
17 The trial was powered to detect a four-point change on the Oxford Hip Score at 
18 52 weeks post procedure.11 Patients in each arm received twice daily 
19 programme-specific physiotherapy sessions until hospital discharge.  In the 
20 conventional arm patients followed the physiotherapy programme used for total 
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1 hip arthroplasty patients. Hip precautions were used and exercises were only 
2 partially weight bearing to help regain range of motion and included isometric 
3 strengthening exercises.1 In the accelerated physiotherapy programme  arm we 
4 did not require patients to follow the various ‘hip precautions’ used in the standard 
5 physiotherapy arm, such as not being allowed to flex hips more than 90° and not 
6 being allowed to cross legs and patients were fully weight bearing from the start 
7 of the programme in hospital. Exercises in this arm were wide ranging and 
8 included on-going gait re-education to increase walking distance, direction, and 
9 reduce reliance on aids, activities to increase the range of hip movement and 
10 lower limb strength, and balance training and weight bearing exercises. At 
11 hospital discharge, patients in each arm of the trial were given a booklet with 
12 guidelines on how to continue with their exercise programme at home for an 8-
13 week period. accelerated physiotherapy programme patients received an 
14 additional rehabilitation session (at home or as an outpatient) two weeks after 
15 surgery. 
16
17 A health economic evaluation, specifically a cost-utility analysis was designed as 
18 an integral part of the trial.12
19
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1 Costing
2 A United Kingdom National Health Service perspective was adopted for the 
3 costing component of the analysis, with costs expressed using 2014/15 United 
4 Kingdom £ Sterling. The costs incurred by the patients were also included in our 
5 analyses as a complementary perspective. 
6
7 During the primary hospitalisation, patients in both arms received two 
8 physiotherapy sessions per day. Thereafter, the physiotherapy received by 
9 patients in the accelerated programme arm differed in terms of precautions and 
10 intensity from the physiotherapy received by patients in standard programme 
11 arm. Both programmes were assumed to consume equivalent amounts of 
12 physiotherapists time with the exception of the accelerated physiotherapy arm 
13 where patients received one additional physiotherapy session at two-weeks post-
14 operation. Therefore, the costs of providing the rehabilitation programmes per se 
15 were not included in the analysis as they would cancel each other out when 
16 comparing costs across trial arms. However, we accounted for and costed the 
17 additional physiotherapist visit received by patients randomised to the 
18 accelerated physiotherapy programme. More details on the intervention were 
19 provided elsewhere.1
20
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1 At 6, 16, and 52 weeks, patients submitted study diaries they had been using to 
2 prospectively record contacts with the National Health Service and with private 
3 health practitioners. Each patient recorded data on the frequency of visits to 
4 general practitioners, practice nurses, outpatient clinics (surgical / non-surgical), 
5 physiotherapists and other health care professionals, and home visits from 
6 general practitioners, nurses and physiotherapists. The occurrence and duration 
7 of any hospital re-admissions (for reasons related to the hip and also for other 
8 non-hip related reasons) was recorded, as well as information on the frequency 
9 and types of visits to private health care practitioners, and on equipment usage 
10 (e.g. sock aids, crutches) and duration. When equipment usage was recorded at 
11 16 weeks but had been discontinued by 52 weeks, usage was assumed to have 
12 continued for half of this 36-week period. Resource use data were costed using 
13 the unit costs shown in Table 1. 
14
15 [please, insert table 1 here]
16
17 Health Outcomes
18 Patients completed the 3-level EuroQol EQ-5D questionnaire at baseline, 6, 16, 
19 and 52 weeks.13 The EQ-5D is a generic health related quality of life instrument 
20 which contains questions on five domains: mobility, self-care, usual activities, 
Page 7 of 43
http://mc.manuscriptcentral.com/clinrehab
Clinical Rehabilitation
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Peer Review
10
1 pain/discomfort and anxiety/depression. Each domain has three levels - no 
2 problems, some problems and extreme problems.13 Patients responses to the 
3 questionnaire provide a unique health state description which can then be 
4 converted into a single index score using a tariff estimated using data from a 
5 sample of the United Kingdom population.14 The single index score is anchored 
6 at zero (reflecting death) and one (reflecting perfect health). Negative scores 
7 signify health states considered to be worse than death. A linear trend was 
8 assumed between a patient’s scores at each time point, and the area under the 
9 resulting curve gave the number of quality adjusted life years experienced by that 
10 patient to 12 months. 15 Quality adjusted life years are a composite measure of 
11 health outcome combining morbidity and mortality associated with a disease or 
12 condition. 
13
14 Statistical analysis
15 We assumed that the probability of data being missing depended on observed 
16 data and not on unobserved data (that is data were missing at random and could 
17 be predicted using other data collected during the trial).
18 Multiple imputation  was used to impute these missing data.16 Multiple imputation 
19 uses regression-based approaches to predict m values for each missing data cell 
20 and so accounts for the uncertainty in the imputation process itself, and enables 
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1 all variables in the dataset (both complete and incomplete) to be used to predict 
2 the values of missing data cells.16 Here, individual regressions were specified for 
3 each variable with missing data, and five values were imputed for each missing 
4 data cell, essentially creating five different datasets. Rubin’s rule was used to 
5 summarise data across imputed datasets when calculating results.16, 17 The 
6 approach accounts for the variance within imputed datasets as well as between 
7 imputed datasets. 
8
9 When summarising resource use, costs, EQ-5D scores and quality adjusted life 
10 years for each trial arm, means and standard errors were used. When comparing 
11 between trial arms, mean differences and 95% confidence intervals (95% CI) 
12 around those differences were calculated. On account of the skewed nature of 
13 the data, non-parametric bootstrapping (using 5,000 replicates) was used to 
14 estimate the confidence intervals.15  
15
16 The mean cost and quality adjusted life years differences were plotted as a single 
17 point on the cost-effectiveness plane, a two-dimensional figure with four 
18 quadrants representing all possible outcome combinations of cost and quality 
19 adjusted life years differences (i.e. accelerated physiotherapy programme costs 
20 more and is less effective than standard physiotherapy, costs more and is more 
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1 effective, costs less and is less effective, and costs less and is more effective).15 
2 As the trial was not powered for cost-utility, uncertainty around the cost-utility 
3 result was examined using non-parametric bootstrapping which utilised sampling 
4 with replacement to simulate 5,000 pairs of mean cost and quality adjusted life 
5 years differences, which were also plotted on the cost-effectiveness plane. Each 
6 cost and quality adjusted life years pair has an associated incremental cost-
7 effectiveness ratio (ICER), calculated by dividing the mean cost difference by the 
8 mean quality adjusted life years difference.15 The ICER represents the change in 
9 costs required to gain one additional quality adjusted life year when moving from 
10 a conventional to a new therapy.  A study’s ICER is routinely benchmarked 
11 against the maximum acceptable ICER, which at £20,000 per quality adjusted life 
12 year is considered to represent society’s maximum willingness to pay  for a quality 
13 adjusted life year.18 In this study, estimating the proportion of the bootstrapped 
14 cost and quality adjusted life years pairs with corresponding ICERs below 
15 £20,000 per quality adjusted life years allowed an estimate to be made of the 
16 probability that accelerated physiotherapy programme will be cost-effective when 
17 compared with conventional physiotherapy.  Varying the maximum willingness to 
18 pay and each time re-calculating the proportion of plotted points with ICERs 
19 below this figure enabled the construction of the cost-effectiveness acceptability 
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1 curve which indicates for varying levels of willingness to pay, the probability that 
2 accelerated physiotherapy programme will be cost-effective.15
3
4 All statistical analyses were performed using Stata SE v12.0 (StatCorp, College 
5 Station, TX, USA).
6
7 Sensitivity Analysis
8 To assess the robustness of results, extensive sensitivity analysis was performed 
9 using alternative values for the driver of cost (i.e. the number of hospitalisations) 
10 and for levels of health related quality of life in the accelerated physiotherapy 
11 programme arm.  The number of hospitalisations in the accelerated 
12 physiotherapy programme arm was increased from the observed estimate in 
13 increments of 25% up to 100%.  We also separately assessed the impact of 
14 health related quality of life experienced in the accelerated physiotherapy 
15 programme arm on our results by simulating 4 scenarios: 1) a reduction of the 
16 quality adjusted life years in the reference case by 15%, 2) a reduction of 7.5%, 
17 3) an increment of 7.5% and 4) an increment of 15%. In scenarios (3) and (4), 
18 the maximum health gain was limited to 1 quality adjusted life year. 
19
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1 A two-way sensitivity analysis combined all possible combinations of the 
2 alternative values used for the two parameters tested in the one-way analyses. 
3
4 Results
5 Demographics
6 Eighty male patients were randomised post-surgery to an accelerated 
7 physiotherapy programme (n=40) or to a conventional physiotherapy programme 
8 (n=40). Figure 1 shows the flow of patients through the trial. 1,19 
9 [Please insert here figure 1]
10 Table 2 shows baseline characteristics for the 80 patients randomised. The two 
11 arms were similar at baseline across most of the clinical measures observed (for 
12 example range of motion) and for patient reported outcomes (for example Hip 
13 disability and Osteoarthritis Outcome Score), with the exception of body mass 
14 index (p=0.019) and flexors muscle strength (p=0.045). The accelerated 
15 physiotherapy programme arm had a lower body mass index than the control arm 
16 (-1.8 Kg m-2) and a reduced strength of the flexors (2.7 NM). 
17 [please, insert here table 2]
18
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1 Costs
2 Twenty-two and a half percent of trial data were missing on resource use and 
3 were imputed using multiple imputation. Table 3 shows mean per patient 
4 resource use and costs for each trial arm.  In the 12 months following resurfacing 
5 hip arthroplasty, patients in the accelerated physiotherapy programme arm made 
6 noticeably fewer visits to surgeons (0.62 v 1.05, p=0.16) and to physiotherapists 
7 (0.94 v 2.32, p<0.05) than their counterparts in the standard physiotherapy arm.  
8 Additionally, accelerated physiotherapy programme patients on average, spent 
9 less time in hospital (for both hip and non-hip related reasons) but did record 
10 more home visits from physiotherapists (0.71 v 0.11, p<0.05), which is not 
11 unexpected given the additional physiotherapy contact (which could be home or 
12 clinic-based) scheduled for these patients at two weeks post-surgery.  
13
14 Considering all National Health Service contacts, mean (standard error) total 
15 costs for the National Health Service were £504 (£104) per patient in the 
16 accelerated physiotherapy programme arm and £706 (£187) in the standard 
17 physiotherapy arm, giving a mean cost difference favouring accelerated 
18 physiotherapy programme of -£200 (95% CI -£656 to £255, p=0.35).  We also 
19 observed a small mean difference in patient costs favouring the accelerated 
20 physiotherapy programme arm (see Table 3). 
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1
2 [Insert here table 3]
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1 Health Outcomes
2 We imputed the ten percent of EQ-5D data that were missing. Figure 2 shows 
3 health related quality of life improved in both arms between baseline and 6 weeks, 
4 and whilst further improvements were seen in the accelerated physiotherapy 
5 programme arm at 16 and 52 weeks, EQ-5D scores in the standard 
6 physiotherapy arm remained relatively stable from 6 weeks onwards. At 52 weeks 
7 mean (standard error) EQ-5D scores were 0.91 (0.03) in the accelerated 
8 physiotherapy programme arm and 0.73 (0.05) in the standard physiotherapy 
9 arm, giving a statistically significant difference favouring accelerated 
10 physiotherapy programme of 0.18 (95% confidence intervals 0.07 to 0.29, 
11 p=0.002).  
12
13 There were no deaths during the trial.  Estimating quality adjusted life years as 
14 the area under each patient’s EQ-5D health related quality of life profile to 12 
15 months showed that accelerated physiotherapy programme patients on average 
16 experienced 0.84 (0.02) quality adjusted life years over the 12-month period and 
17 standard physiotherapy patients experienced 0.71 (0.03) quality adjusted life 
18 years. The mean quality adjusted life years difference of 0.13 (95% confidence 
19 intervals 0.05 to 0.21, p=0.002) favoured the accelerated physiotherapy 
20 programme and was statistically significant. 
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1
2  [please insert here figure 2]
3
4 Cost-effectiveness
5 Analysis showed that on average and when compared with standard 
6 physiotherapy, the accelerated physiotherapy programme was associated with 
7 cost savings to the National Health Service of £200 per patient and a significant 
8 gain of 0.13 quality adjusted life years.  Figure 3 shows the plot of the 5,000 
9 bootstrapped cost and quality adjusted life years difference pairs on the cost-
10 effectiveness plane and shows that the majority (86%) fall within the South-East 
11 quadrant on the plane where the accelerated physiotherapy programme is more 
12 effective and less costly than standard physiotherapy. A proportion of points do 
13 however fall within the North East quadrant suggesting there is a potential for 
14 accelerated physiotherapy programme to be more effective but also more costly 
15 than standard physiotherapy. None of these points however produced an ICER 
16 (calculated by dividing the difference in cost by the difference in quality adjusted 
17 life years) greater than £10,000, which is below the value of £20,000 which is 
18 thought to represent society’s maximum willingness to pay for a quality adjusted 
19 life year in the United Kingdom.  Figure 4 shows for the reference case, the 
20 probability that accelerated physiotherapy programme is cost-effective when 
Page 16 of 43
http://mc.manuscriptcentral.com/clinrehab
Clinical Rehabilitation
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Peer Review
19
1 compared to standard physiotherapy, for different values of maximum willingness 
2 to pay for a quality adjusted life year. Assuming the maximum willingness to pay 
3 per quality adjusted life year is £20,000, the accelerated physiotherapy 
4 programme is cost-effective – namely the cost-effectiveness probability is one.
5
6 [please insert here figure 3]
7 [please insert here figure 4]
8
9 Sensitivity analysis
10 Among all the assessed scenarios reported in Table 4, none changed the 
11 resulting cost differences in terms of statistical significance. Our cost results were 
12 sensitive only to more extreme assumptions; for example doubling the 
13 hospitalisation cost reduced the mean cost difference from -£200 in favour of 
14 accelerated physiotherapy programme to -£4 (95% confidence intervals: -£554 
15 to £546). Nevertheless, the probability that accelerated physiotherapy 
16 programme is cost-effective for willingness to pay values above £5,000 per 
17 quality adjusted life year was unaffected by inflating the number of 
18 hospitalisations in the accelerated physiotherapy programme arm (figure 4, panel 
19 a). On the other hand, quality adjusted life year results were more sensitive to 
20 changes. Reducing the quality adjusted life years of accelerated physiotherapy 
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1 programme patients by 7.5%, the between arm difference was no longer 
2 significant (0.07 QALYs; 95% confidence intervals -0.01 to 0.14). The probability 
3 that accelerated physiotherapy programme is cost-effective for willingness to pay 
4 values above £5,000 per quality adjusted life year however remained virtually 
5 unaltered for most of the quality adjusted life year scenarios (figure 4, panel b). 
6 Only reducing the quality adjusted life years in the accelerated physiotherapy 
7 programme arm by 15% resulted in higher uncertainty as to whether accelerated 
8 physiotherapy programme is cost-effective (figure 4, panel b).  
9
10 Table 5 combined the values used in the one-way sensitivity analyses presented 
11 in Table 4 and shows the probabilities that the accelerated physiotherapy 
12 programme is cost–effective assuming the maximum willingness to pay per 
13 quality adjusted life year is £20,000.  These probabilities are calculated by 
14 identifying the proportion of all bootstrap replicates giving an incremental cost-
15 effectiveness ratio lower than £20,000 per quality adjusted life year, with a value 
16 of 1 indicating 100% of points fall below this threshold. A potential decrement in 
17 the health related quality of life of the accelerated physiotherapy programme 
18 patients by 15% would reduce the probability of it being cost-effective to a range 
19 between 0.61 (accelerated physiotherapy programme hospitalisation rate: 
20 reference case) and 0.52 (accelerated physiotherapy programme hospitalisation 
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1 rate: +100%), as shown in Table 5. The results of the sensitivity analysis 
2 suggested that accelerated physiotherapy programme is very likely to be cost 
3 effective, unless patients’ would experience a substantial lower health related 
4 quality of life than our estimates (i.e. 15% decrement in health related quality of 
5 life).
6
7 [insert here table 4 and table 5] 
8
9 Discussion
10 The current economic evaluation showed that an accelerated physiotherapy 
11 programme is likely to be a cost-effective alternative to standard physiotherapy 
12 following resurfacing hip arthroplasty in young male patients. Total National 
13 Health Service costs incurred during the 12 months following the resurfacing hip 
14 arthroplasty were lower in the accelerated physiotherapy programme arm by an 
15 average of £200, although this cost difference did not achieve statistical 
16 significance.  
17
18 The lower cost in the accelerated physiotherapy programme arm was primarily 
19 due to patients needing to spend less time in hospital than their standard 
20 physiotherapy counterparts during the 12-month study period.  Whilst this could 
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1 have been because accelerated physiotherapy programme patients were on 
2 average mobilised quicker and may have been less susceptible to complications 
3 (the reduction in hip-related hospital admissions with accelerated physiotherapy 
4 accounted for almost half of the total cost saving at (-£93)), one must 
5 acknowledge that hospital re-admission costs in both groups were generally very 
6 low and this finding may have been a chance occurrence.
7  
8 This study showed that when compared with standard physiotherapy, patients 
9 who had received accelerated physiotherapy on average reported significantly 
10 better health related quality of life on the EQ-5D questionnaire at 12 months after 
11 resurfacing hip arthroplasty and gained a significantly greater number of quality 
12 adjusted life years over the study time horizon.  Such findings are intuitive given 
13 the clinical results of the trial which showed that the accelerated physiotherapy 
14 programme  significantly improved clinical outcomes, including levels of hip 
15 disability, osteoarthritis and activity ability.1  It would appear that with accelerated 
16 physiotherapy, faster mobilisation, a reduction in limitations due to range of 
17 motion, and improved confidence due to absence of hip precautions, all translate 
18 into a better sense of overall wellbeing for patients.
19
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1 The number of studies focusing on the effects of different forms of rehabilitation 
2 following resurfacing hip arthroplasty is limited.  Indeed, the trial on which this 
3 economic evaluation was based was included in a recent systematic literature 
4 review, which identified only three other papers, one based on a case-series and 
5 two reporting individual case studies.5 Therefore, the comparison of our results 
6 with those from the literature is problematic. 
7  
8 Edlin et al. did assess the cost-effectiveness of resurfacing hip arthroplasty 
9 versus total hip arthroplasty  and in doing so, reported the cost of standard care 
10 rehabilitation after resurfacing hip arthroplasty , permitting a comparison with the 
11 cost results reported here for the standard physiotherapy arm.20  The patients 
12 involved in the Edlin et al. study were also recruited in the United Kingdom  and 
13 the analysis was performed from a United Kingdom National Health Service 
14 perspective. On average, patients in the Edlin study had a higher cost per patient 
15 (at 12 months follow up) than seen here: £942 versus £705.20 This difference, 
16 although not substantial could be attributable to demographic characteristics and 
17 the worse health status of the patients enrolled in the Edlin et al study. The mean 
18 EQ-5D score recorded at baseline (0.31 (95% CI: 0.22 to 0.39)) was lower than 
19 the corresponding score we report here, 0.53 (95% CI: 0.45 to 0.61).20 
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1 Also, 37% of individuals recruited by Edlin et al. were women, who were shown 
2 to have higher expenses than their male counterparts. Poorer health could 
3 therefore have led to greater requirements for healthcare and thus higher costs.  
4 Interestingly, both studies identified hospitalisation as the major cost driver at 12 
5 months. The inpatient cost in the resurfacing hip arthroplasty arm of that study 
6 accounted for almost 50% of the total cost (£942) excluding the cost of primary 
7 operation.20 Similarly, the hospitalisation cost in our study accounted for 48% of 
8 the total cost (£705) in the standard physiotherapy arm.
9
10 There are several limitations that should be considered when interpreting the 
11 results of the current study.  Firstly, our results are based on patients receiving 
12 metal-on-metal resurfacing hip arthroplasty. The number of patients accessing to 
13 metal-on-metal resurfacing hip arthroplasty is currently limited mainly because of 
14 the recent concern surrounding metal-on-metal side-effects (e.g. pseudotumors 
15 and elevated metal ions levels).21 Nevertheless, we still believe our findings could 
16 be applicable to other patient populations including those undergoing large-
17 diameter resurfacings (e.g. ceramic-on-ceramic) and the general hip arthroplasty 
18 population.  However, future studies should confirm our findings in these 
19 alternative patient groups. 
20
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1 Secondly, the time horizon of our analysis is limited to 12 months of follow-up. 
2 Although the short time period of this study might exclude costly events (such as 
3 revision following resurfacing hip arthroplasty), this analysis focused on the post-
4 operative recovery of function.  
5
6 Thirdly, this trial enrolled exclusively male patients, limiting the applicability of our 
7 study to a broader population. According to the findings from Edlin et al, females 
8 incurred higher costs and received a smaller health related quality of life benefit 
9 than men after standard physiotherapy.20 Using the sensitivity analysis presented 
10 in this paper, we can contemplate the potential implications for the results had 
11 women been included in our study.  Scenario analyses showed that even when 
12 costs were increased and the quality adjusted life year gain was reduced, the 
13 accelerated physiotherapy programme remained the cost-effective alternative in 
14 all scenarios except those in which the quality adjusted life year gain with 
15 accelerated physiotherapy was reduced by a maximum of 15% (Table 5). 
16 Additionally, the sensitivity analysis results also confirmed the impact of changes 
17 to the hospitalisation cost on overall results is marginal when compared to the 
18 influence of changes to HRQoL. 
19
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1 Finally, our analysis used nationally representative unit costs to value resource 
2 use data from a single study centre.  Whilst we acknowledge that it would have 
3 been possible to source and use locally available unit costs, ultimately, we felt 
4 this approach would diminish the generalizability of the study findings and its 
5 usefulness to readers in different geographical locations.
6
7 This study provides the first reported evidence on the cost-effectiveness of an 
8 accelerated physiotherapy programme when compared with standard 
9 physiotherapy for male pati nts who have undergone resurfacing hip 
10 arthroplasty.  Our findings suggest that an accelerated physiotherapy programme 
11 is likely to be a cost-effective alternative to standard physiotherapy following 
12 resurfacing hip arthroplasty, with the results being largely driven by improvements 
13 in health related quality of life reported by accelerated physiotherapy programme 
14 patients during the course of the study. Therefore, the adoption of a more intense 
15 rehabilitation programme is not only likely to improve the clinical and quality of 
16 life outcomes of patients following resurfacing hip arthroplasty, but it also may 
17 represents good value for money for the National Health Service.1 
18
19
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1 Clinical Messages 
2 An accelerated physiotherapy programme significantly improves health-related 
3 quality of life and may reduce costs in young resurfacing hip arthroplasty male 
4 patients.
5 A tailored protocol for rehabilitation in resurfacing hip arthroplasty patients is very 
6 likely to offer a cost-effective use of resources (the probability of it being cost-
7 effective at a willingness to pay value of £5,000 per quality adjusted life year is 
8 one).
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1 Table 1. Unit costs used in the analysis (United Kingdom £ 2014/15)
Resource unit Unit price Source
 
Home Visits
General practitioner £100 PSSRU22
Nurse £38 PSSRU22
Physiotherapist £50 PSSRU22
Other* £59.5 PSSRU22
 
Health Care Practice Visits
General practitioner £24 PSSRU22
Nurse £11 PSSRU22
Surgeon £115 National schedule of reference costs23
Doctor – Other £135 National schedule of reference costs23
Physiotherapist £36 PSSRU22
Other* £64.2 PSSRU22
 
Private Health Care Visits
General Practitioner £24 PSSRU22
Nurse £11 PSSRU22
Physiotherapist £45 BUPA24
Occupational therapist £45 BUPA24
Osteopath £52.80 BUPA24
Chiropractor £55 UK Healthcare Centre25
Other* £36 BUPA24
 
Hospitalization day
Not related to hip £345 National schedule of reference costs23
Related to hip £316 National schedule of reference costs23
 
Equipment† £0.61 PSSRU22
Acronyms: Personal Social Service Research Units (PSSRU), United Kingdom (UK), British united provident association (BUPA).
* E.g. Types of other visits were not specified and so when costing, we use a unit cost averaged across specified types of contacts. 
† Equipment includes: crutches, sticks, sock aid, raised toilet seat, shoe horn, helping hand, bath board, chair/bed raiser and other. 
Equipment unit price are reported as cost per week, but sock aid and shoe horn as item cost.
2
3
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1 Table 2. Demographic characteristics
Baseline characteristics
Standard 
Programme
(n=40)
Accelerated 
Programme
(n=40) p value
Age at operation (years), median (IQR) 55.8 (49.0,61.0) 55.8 (49.1,59.0) 0.535
BMI (kg/m2), average (s.d.) 29.2 (3.8) 27.4 (2.9) 0.019
Preoperative OHS, average (s.d.) 27.1 (8.5) 25.0 (7.8) 0.253
Preoperative HOOS, average (s.d.) 50.6 (15.3) 47.3 (14.1)
Preoperative rescaled HOOS, average (s.d.)
Total 50.6 (15.3) 47.3 (14.1) 0.317
Symptoms 51.7 (19.5) 46.9 (18.3) 0.261
Stiffness 45 (19.4) 44.7 (16.2) 0.938
Pain 51.6 (15.4) 47.3 (13.9) 0.185
Function - daily living 59.3 (16.8) 54.2 (17.2) 0.183
Function - sports activities 35 (20.2) 32.0 (19.6) 0.506
Quality of life 30 (16.3) 34.2 (19.6) 0.236
Preoperative UCLA activity score, median 
(IQR) 4.5 (3,6) 5.5 (3.5,7) 0.083
ROM Flexion (degrees), average (s.d.) 85.3 (17.1) 82.2 (19.3) 0.449
ROM Extension (degrees), average (s.d.) 16.2 (13.1) 18.4 (14.9) 0.486
ROM Abduction (degrees), average (s.d.) 19.2 (7.3) 18.9 (9.7) 0.898
Muscle strength Flexion (degrees), average 
(s.d.) 16.8 (6.7) 14.1 (4.9) 0.045
Muscle strength Abduction (degrees), 
average (s.d.) 13.2 (5.4) 12.2 (4.4) 0.339
Muscle strength Extension (degrees), 
average (s.d.) 13.9 (5.2) 12.0 (5.1) 0.106
EQ5D utility at baseline average (s.d.) 0.53 (0.26) 0.49 (0.30) 0.529
EQ-5D-3L Visual Analogue Scale, average 
(s.d.) 64.3 (20.50) 63.95 (20.00) 0.939
Acronyms: Interquartile range (IQR), Body Mass Index (BMI), standard deviation (s.d.), Oxford Hip Score 
(OHS), Hip disability and Osteoarthritis Outcome Score (HOOS), University of California, Los Angeles 
(UCLA) activity score, range of motion (ROM), EuroQol 5 dimension three level (EQ-5D-3L)
2
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1 Table 3. Follow-on health service and private resource use and costs (2014/15 United Kingdom £) to 12 months
Resource Item Standard Programme n=40
Accelerated 
Programme n=40
Standard Programme 
n=40
Accelerated 
Programme n=40  
Mean (s.e.) Mean (s.e.) Mean cost difference  Mean (s.e.) resource use per patient
Mean (s.e.) resource 
use per patient cost per patient cost per patient (95% CI)
Home Visits From
 General Practitioner 0.04 (0.03) 0.08 (0.08) £4.00 (£3.47) £8.00 (£7.67) £4.00 (-£12.60 to £20.60)
 Nurse 0.20 (0.17) 0.41 (0.17) £7.60 (£6.57) £15.39 (£6.47) £7.8 (-£11.17 to £26.75)
 Physiotherapist 0.11 (0.08)  0.71 (0.09) £5.50 (£4.21) £35.25 (£4.69) £29.75 (£17.92 to £41.58)†
 Other 0.1 (0.07) 0.06 (0.04) £5.95 (£3.91) £3.57 (£2.61) -£2.38 (-£11.85 to £7.09)
Patient Visits To
 General Practitioner 1.21 (0.27) 0.88 (0.20) £28.92 (£6.42) £21.12 (£4.86) -£7.8 (-£22.27 to £6.67)
 Nurse 1.75 (0.45) 1.68 (0.34) £19.20 (£4.91) £18.48 (£3.78) -£0.71 (-£14.74 to £13.31)
 Surgeon 1.05 (0.32) 0.62 (0.23) £120.75 (£36.44) £70.25 (£26.70) -£50.03(-£143.72 to £43.67)
 Hospital doctor 0.41 (0.15) 0.27 (0.13) £54.68 (£20.62) £36.45 (£17.48) -£18.23(-£74.51 to £38.06)
 Physiotherapist 2.32 (0.58)  0.94 (0.43) £83.34 (£20.78) £33.84 (£15.57) -£49.5 (-£100.30 to £1.29)
 Other 0.50 (0.20) 0.33 (0.15) £32.10 (£12.94) £21.19 (£9.48) -£10.91 (-£43.05 to £21.22)
 Inpatient Hospital Days
 Related to hip 0.66 (0.34) 0.37 (0.19) £209.35 (£109.01) £116.13 (£59.15) -£93.22 (-£336.16 to £149.72)
 Unrelated to hip 0.38 (0.16) 0.23 (0.14) £131.20 (£56.40) £79.75 (£48.69) -£51.45 (-£232.07 to £129.17)
Equipment Various Various £2.24 (£0.24) £1.60 (£0.21) -£0.64 (-£1.29 to -£0.0003)*
Total follow-on NHS Costs -- -- £704.58 (£186.97) £504.36 (£104.26) -£200.23 (-£655.50 to £255.05)
Private Healthcare Visits To
 General Practitioner 0.05 (0.05) 0.03 (0.03) £1.08 (£1.21) £0.72 (£0.72) -£0.36 (-£3.70 to £2.98)
 Nurse 0.00 (0.00) 0.00 (0.00) £0.00 (£0.00) £0.00 (£0.00) £0.00 (--)
 Physiotherapist 1.13 (0.49) 1.01  (0.42) £50.63 (£21.90) £45.23 (£18.84) -£5.40 (-£66.70 to £55.90)
 Occupational Therapist 0.00 (0.00) 0.00 (0.00) £0.00 (£0.00) £0.00 (£0.00) £0.00 (--)
 Osteopath 0.27 (0.22) 0.26 (0.19) £14.00 (£11.68) £13.46 (£10.17) -£0.53 (-£35.08 to £34.02)
 Chiropractor 0.00 (0.00) 0.00 (0.00) £0.00 (£0.00) £0.00 (£0.00) £0.00 (--)
 Other 0.29 (0.21) 0.00 (0.00) £10.44 (£7.62) £0.00 (£0.00) -£10.44 (-£25.85 to £4.97)
Total follow-on Private Costs -- -- £76.14 (£32.43) £59.41 (£23.90) -£16.73 (-£102.43 to £68.97)
Acronyms: Confidence interval (CI), standard error (s.e.).
* p<0.05
† p<0.01
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1 Table 4. One-way sensitivity analysis results: Varying hospitalisation costs 
2 and levels of health related quality of life in the accelerated physiotherapy 
3 programme arm
Cost Mean total costs Incremental costs* 95% CI
Standard physiotherapy £704.58
APP - Reference case £504.36 -£200.22 -£655.50 to £255.05
APP Hospitalisations: 
+25% £553.33 -£151.25 -£627.33 to £324.82
APP Hospitalisations: 
+50% £602.30 -£102.28 -£601.29 to £396.72
APP Hospitalisations: 
+75% £651.27 -£53.31 -£577.09 to £470.46
APP Hospitalisations: 
+100% £700.24 -£4.34 -£554.48 to £545.79
HRQoL  Mean total QALYs
 Incremental 
QALYs†  95% CI
Standard physiotherapy 0.71
APP - Reference case 0.84 0.13 QALY 0.05 QALY to 0.20 QALY
APP QALY: -15% 0.71 0.0025 QALY -0.07 QALY to 0.07 QALY
APP QALY: -7.5% 0.78 0.07 QALY -0.01 QALY to 0.14 QALY
APP QALY: +7.5% 0.89 0.18 QALY 0.10 QALY to 0.26 QALY
APP QALY: +15% 0.92 0.21 QALY 0.14 QALY to 0.29 QALY
Acronyms: Confidence interval (CI), accelerated physiotherapy programme (APP), health related quality of life (HRQoL), quality adjusted 
life years (QALYs).
* Values calculated by taking the difference in costs between each specific scenario in the APP arm and the standard physiotherapy arm.
† Values calculated by taking the difference in QALYs between each specific scenario in the APP arm and the standard physiotherapy 
arm.
4
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1 Table 5. Two-way sensitivity analysis results: The probability that 
2 accelerated physiotherapy programme is cost–effective at a willingness to 
3 pay of £20,000 per quality adjusted life years for varying estimates of 
4 hospitalisation cost and health related quality of life.
 
APP - 
Reference 
case
APP +25% 
hospitalisation
APP +50% 
hospitalisation
APP +75% 
hospitalisation
APP +100% 
hospitalisation
     
APP - Reference 
case 1.00 1.00 1.00 1.00 1.00
 APP QALY: -15% 0.61 0.59 0.57 0.54 0.52
APP QALY: -7.5% 0.97 0.97 0.96 0.96 0.95
APP QALY: 7.5% 1.00 1.00 1.00 1.00 1.00
APP QALY: 15% 1.00 1.00 1.00 1.00 1.00
Acronyms: accelerated physiotherapy programme (APP), quality adjusted life years (QALY)
5
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7
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1
2
3 Figure 1. Flow of participants
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1 Figure 2. Mean EQ-5D utility scores and 95% confidence intervals by time 
2 point and trial arm.
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1
2
3
4 Figure 3. Cost-effectiveness plane showing 5000 bootstrapped pairs of cost 
5 and quality adjusted life year differences
6
7
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1 Figure 4. Cost-effectiveness acceptability curves: reference case and one-way sensitivity analyses 
2 varying hospitalisation cost (panel a) and quality adjusted life years (panel b) observed in 
3 accelerated physiotherapy programme arm.
4
5
6 Acronyms: accelerated physiotherapy programme (APP), quality adjusted life years (QALY)
7
Page 38 of 43
http://mc.manuscriptcentral.com/clinrehab
Clinical Rehabilitation
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Peer Review
CONSORT 2010 checklist  for clinical trials
Section /Topic Item 
No
Checklist Item Reported 
on Page 
No
Title and abstract
1a Identification as a randomised trial in the title 1
1b Structured summary of trial design, methods, results and 
conclusions (for specific guidance see CONSORT for abstracts)
2-3
Introduction
Background and objectives 2a Scientific background and explanation of rationale 5
2b Specific objectives or hypotheses 5
Methods
Trial design 3a Description of trial design(such as parallel, factorial) including 
allocation ratio
6
3b Important changes to methods after trial commencement (such 
as eligibility criteria), with reasons
6
Participations 4a Eligibility criteria for participants 6
4b Settings and locations where the data were collected 6
Interventions 5 The interventions for each group with sufficient details to allow 
replication, including how and when they were actually 
administered
6-7
Outcomes 6a Completely defined pre-specified primary and secondary 
outcome measures, including how and when they were assessed
6-9
6b Any changes to trial outcomes after the trial commenced, with 
reasons
6
Sample size 7a How sample size was determined 6
7b When applicable, explanation of any interim analyses and 
stopping guidelines
6
Randomisation
Sequence generation 8a Method used to generate the random allocation sequence 6
8b Type of randomisation, details of any restriction (such as 
blocking and block size)
6
Allocation concealment
mechanism
9 Mechanism used to implement the random allocation sequence 
(such as sequentially numbered containers), describing any 
steps taken to conceal the sequence until interventions were 
assigned
6
Implementation 10 Who generated the random allocation sequence, who enrolled 
participants, and who assigned participants to interventions
6
Blinding 11a If done, who was blinded after assignment to interventions (for 
example, participants, care providers, those assessing 
outcomes) and how
N/A
11b If relevant, description of the similarity of interventions N/A
Statistical methods 12a Statistical methods used to compare groups for primary and 
secondary outcomes
10-13
12b Methods for additional analyses, such as subgroup analyses and 
adjusted analyses
12
Results
Participant flow (a diagram 
is strongly recommended)
13a For each group, the numbers of participants who were 
randomly assigned, received intended treatment, and were 
analysed for primary outcome
14
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13b For each group, losses and exclusions after randomisation, 
together with reasons
14
Recruitment 14a Dates defining the periods of recruitment and follow-up 6
14b Why the trial ended or was stopped N/A
Baseline data 15 A table showing baseline demographic and clinical 
characteristics for each group
14
Number analysed 16 For each group, number of participants (denominator) included 
in each analysis and whether the analysis was by original 
assigned groups
16
Outcomes and estimation 17a For each primary and secondary outcomes, results for each 
group, and the estimated effect size and its precision (such as 
95% confidence interval)
15-17
17b For binary outcomes, presentation of both absolute and relative 
effect sizes in recommended
N/A
Ancillary analyses 18 Results of any other analyses perform, including subgroup 
analyses and adjusted analyses, distinguishing pre-specified 
from exploratory
17-18
Harms 19 All important harms or unintended effects in each group (for 
specific guidance see CONSORT for harms [28])
6
Discussion
Limitations 20 Trial limitations, addressing sources of potential bias, 
imprecision, and, if relevant, multiplicity of analyses
24-26
Generalisability 21 Generalisability (external validity, applicability) of trial 
findings
23-24
Interpretation 22 Interpretation consistent with results, balancing benefits and 
harms, and considering other relevant evidence
21-23
Other information
Registration 23 Registration number and name of trial registry 3
Protocol 24 Where the full trial protocol can be accessed, if available 6
Funding 25 Sources of funding and other support (such as supply of drugs), 
role of funders
23
 
Page 40 of 43
http://mc.manuscriptcentral.com/clinrehab
Clinical Rehabilitation
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Peer Review
CHEERS checklist—Items to include when reporting economic evaluations of health 
interventions
Section/item
Item 
No Recommendation
Reported on page No/ 
line No
Title and abstract
Title 1 Identify the study as an economic evaluation or use 
more specific terms such as “cost-effectiveness 
analysis”, and describe the interventions compared.
P:1
Abstract 2 Provide a structured summary of objectives, 
perspective, setting, methods (including study design 
and inputs), results (including base case and 
uncertainty analyses), and conclusions.
P:2-3
Introduction
Provide an explicit statement of the broader context 
for the study.
P:5Background and 
objectives
3
Present the study question and its relevance for 
health policy or practice decisions.
P:5
Methods
Target population and 
subgroups
4 Describe characteristics of the base case population 
and subgroups analysed, including why they were 
chosen.
P:6
Setting and location 5 State relevant aspects of the system(s) in which the 
decision(s) need(s) to be made.
P:6
Study perspective 6 Describe the perspective of the study and relate this 
to the costs being evaluated.
P:8
Comparators 7 Describe the interventions or strategies being 
compared and state why they were chosen.
P:6-7
Time horizon 8 State the time horizon(s) over which costs and 
consequences are being evaluated and say why 
appropriate.
P:8-9
Discount rate 9 Report the choice of discount rate(s) used for costs 
and outcomes and say why appropriate.
N/A
Choice of health 
outcomes
10 Describe what outcomes were used as the measure(s) 
of benefit in the evaluation and their relevance for 
the type of analysis performed.
P:9-10
11a Single study-based estimates: Describe fully the 
design features of the single effectiveness study and 
why the single study was a sufficient source of clinical 
effectiveness data.
P:6-7, 17Measurement of 
effectiveness
11b Synthesis-based estimates: Describe fully the methods 
used for identification of included studies and 
synthesis of clinical effectiveness data.
N/A
Measurement and 
valuation of preference 
based outcomes
12 If applicable, describe the population and methods 
used to elicit preferences for outcomes.
P:9-10
13a Single study-based economic evaluation:Describe 
approaches used to estimate resource use associated 
with the alternative interventions. Describe primary 
or secondary research methods for valuing each 
resource item in terms of its unit cost. Describe any 
adjustments made to approximate to opportunity 
costs.
P:8-9
Estimating resources and 
costs
13b Model-based economic evaluation: Describe 
approaches and data sources used to estimate 
N/A
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Section/item
Item 
No Recommendation
Reported on page No/ 
line No
resource use associated with model health states. 
Describe primary or secondary research methods for 
valuing each resource item in terms of its unit cost. 
Describe any adjustments made to approximate to 
opportunity costs.
Currency, price date, and 
conversion
14 Report the dates of the estimated resource quantities 
and unit costs. Describe methods for adjusting 
estimated unit costs to the year of reported costs if 
necessary. Describe methods for converting costs into 
a common currency base and the exchange rate.
P:8
Choice of model 15 Describe and give reasons for the specific type of 
decision-analytical model used. Providing a figure to 
show model structure is strongly recommended.
N/A
Assumptions 16 Describe all structural or other assumptions 
underpinning the decision-analytical model.
N/A
Analytical methods 17 Describe all analytical methods supporting the 
evaluation. This could include methods for dealing 
with skewed, missing, or censored data; extrapolation 
methods; methods for pooling data; approaches to 
validate or make adjustments (such as half cycle 
corrections) to a model; and methods for handling 
population heterogeneity and uncertainty.
P:10-13
Results
Study parameters 18 Report the values, ranges, references, and, if used, 
probability distributions for all parameters. Report 
reasons or sources for distributions used to represent 
uncertainty where appropriate. Providing a table to 
show the input values is strongly recommended.
N/A
Incremental costs and 
outcomes
19 For each intervention, report mean values for the 
main categories of estimated costs and outcomes of 
interest, as well as mean differences between the 
comparator groups. If applicable, report incremental 
cost-effectiveness ratios.
P: 15-19
20a Single study-based economic evaluation:Describe the 
effects of sampling uncertainty for the estimated 
incremental cost and incremental effectiveness 
parameters, together with the impact of 
methodological assumptions (such as discount rate, 
study perspective).
P:19-21Characterising uncertainty
20b Model-based economic evaluation: Describe the 
effects on the results of uncertainty for all input 
parameters, and uncertainty related to the structure 
of the model and assumptions.
N/A
Characterising 
heterogeneity
21 If applicable, report differences in costs, outcomes, or 
cost-effectiveness that can be explained by variations 
between subgroups of patients with different baseline 
characteristics or other observed variability in effects 
that are not reducible by more information.
N/A
Discussion
Study findings, limitations, 
generalisability, and 
current knowledge
22 Summarise key study findings and describe how they 
support the conclusions reached. Discuss limitations 
and the generalisability of the findings and how the 
findings fit with current knowledge.
P:21-22, 
24-25,24 
Other
Source of funding 23 Describe how the study was funded and the role of P:28
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Section/item
Item 
No Recommendation
Reported on page No/ 
line No
the funder in the identification, design, conduct, and 
reporting of the analysis. Describe other non-
monetary sources of support.
Conflicts of interest 24 Describe any potential for conflict of interest of study 
contributors in accordance with journal policy. In the 
absence of a journal policy, we recommend authors 
comply with International Committee of Medical 
Journal Editors recommendations.
28
For consistency, the CHEERS statement checklist format is based on the format of the CONSORT statement checklist
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